Satellos Bioscience Inc.

MSCLF

$93M

Micro Cap

NASDAQBiotechnology🇺🇸North America14 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

14w

Drug Pipeline

Drug Name	Phase	Indication	Designations
SAT-3247	Phase 2	Duchenne Muscular Dystrophy	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Mar 31, 2026SAT-3247

Primary completion for SAT-3247 trial (NCT07287189) in Duchenne Muscular Dystrophy

Regulatory Approvals

MSCLF News